Ticker

Meet with Modular Medical CEO Jeb Besser There are 4.8 million individuals with diabetes in the US that require daily insulin. Only 20% currently use an insulin pump.

SAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the "Offering") consisting of 750,000 shares of the Company's common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are…

SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq Capital Market's minimum bid price continued listing requirement. The letter…

First Removable 2-Part Design Targets $3 Billion "Almost-Pumper" Market with Expected Q2 2026 initial deployment. Key Milestones & Investment Highlights: FDA 510(k) Clearance Achieved: Pivot™ pump now cleared for commercial sale in the U.S. - major de-risking event unlocking revenue path.

EssilorLuxottica (OTCMKTS:ESLOY - Get Free Report) and Modular Medical (NASDAQ: MODD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations. Analyst Ratings This is a summary of recent ratings